This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Darden University of Virginia (USA)
-
Option Greeks, Insider Trading, and the Heinz Acquisition
Tomio, Davide; Augustin, Patrick; Brenner, Menachem; Subrahmanyam, MartiCase DARDEN-F-1978-EFinanceJust before Warren Buffett’s company, Berkshire Hathaway Inc, acquired H. J. Heinz Company on February 14, 2013, rumors had been circulating that the Omaha investing oracle had set eyes on the condiment giant. By the time the official acquisition was announced, questions had arisen about some unusual trading activity in financial markets. A very profitable trade was made on the option market just a few days before the announcement: a $90,000 trad...Starting at €8.20
-
Option Greeks, Insider Trading, and the Heinz Acquisition
Tomio, Davide; Augustin, Patrick; Brenner, Menachem; Subrahmanyam, MartiCase DARDEN-F-1978FinanceJust before Warren Buffett’s company, Berkshire Hathaway Inc, acquired H. J. Heinz Company on February 14, 2013, rumors had been circulating that the Omaha investing oracle had set eyes on the condiment giant. By the time the official acquisition was announced, questions had arisen about some unusual trading activity in financial markets. A very profitable trade was made on the option market just a few days before the announcement: a $90,000 trad...Starting at €8.20
-
The Sanofi-Aventis Acquisition of Genzyme: Contingent Value Rights
Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCase DARDEN-F-1715-EFinanceThis case is designed for MBA students in M&A or derivatives courses. In January 2011, Sanofi-Aventis was finalizing its offer terms for acquiring Genzyme. The M&A valuation disputes were about the market potential of alemtuzumab, a drug in Genzyme’s pipeline, and how quickly Genzyme could resolve some of its manufacturing issues. To bridge the gap in their estimates, advisers had suggested an up-front cash payment and a contingent value right (C...Starting at €8.20
-
Sanofi-Aventis's Tender Offer for Genzyme
Eades, Kenneth M.; Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCase DARDEN-F-1716-EFinanceIn October 2010, Henri Termeer, the chairman and CEO of Genzyme, received a letter from the CEO of Sanofi-Aventis announcing its intention to commence a tender offer for Genzyme. Termeer thought the offer undervalued Genzyme, given the number of promising new drugs in the company’s pipeline and the success of its current drug portfolio. The case focuses on the strategic and financial considerations of a large corporate acquisition. To estimate Ge...Starting at €8.20
-
Option Greeks, Insider Trading, and the Heinz Acquisition - Teaching Note
Tomio, Davide; Augustin, Patrick; Brenner, Menachem; Subrahmanyam, MartiTeaching Note DARDEN-F-1978TNFinanceTeaching note for product F-1978Starting at €0.00
-
Option Greeks, Insider Trading, and the Heinz Acquisition - Teaching Note
Tomio, Davide; Augustin, Patrick; Brenner, Menachem; Subrahmanyam, MartiTeaching Note DARDEN-F-1978TN-EFinanceTeaching Note for product F-1978Starting at €0.00